Navigation Links
Case Western Reserve awarded $1.57M for corneal infection research
Date:10/7/2009

Researchers at Case Western Reserve University School of Medicine have been awarded a $1.57 million renewal grant from the National Eye Institute (NEI) of the National Institutes of Health to continue their study of corneal infections, specifically, bacterial keratitis, associated with contact lens wear. The grant will extend the work initiated last year with the receipt of a $2.4 million, five-year grant from the NEI.

The funding will support for four years the work of Eric Pearlman, Ph.D., professor and research director in the Department of Ophthalmology and Visual Sciences, as well as two postdoctoral investigators and one student working toward a Ph.D. The researchers hope to discover specific toll-like receptor (TLR) antagonists to regulate corneal inflammation, which could lead to the development of novel anti-inflammatory medications that could serve as alternatives to steroids to treat the infections.

Bacterial keratitis is a serious cause of visual impairment not only in the United States but also worldwide, and contact lens wear is a major risk factor for the infection in the cornea, the clear covering over the front part of the eye.

"Organisms can infiltrate an intact cornea of a lens-wearer, and a biofilm can form on the contact lens," Dr. Pearlman says. Although correctly performed cleaning of contact lenses can remove the biofilm, or aggregation of micro-organisms, he adds, "When one considers that 34 million people in the United States and about 140 million people worldwide wear contact lenses, even a low percentage of side effects translates into a large number of affected individuals."

The TLR family of pathogen recognition molecules plays a critical role in recognizing and responding to pathogens in the body, initiating anti-microbial inflammatory responses to them that often result in damage to tissue. In the absence of live bacteria, TLRs also respond to microbial products and can induce an inflammatory response in the cornea.

With the latest grant, the researchers will study the activation of TLR4, which is the major stimulatory component of Gram-negative bacteria, by large molecules called lipopolysaccharides, which elicit strong immune responses. They also will examine responses inside epithelial cells in the human cornea and in a murine model of corneal inflammation. The investigators' goal will be to identify potential areas on the cell surface and inside the cells that would be good targets for anti-inflammatory intervention.

Dr. Pearlman is the principal investigator leading a multidisciplinary team investigating fungal and bacterial keratitis that also includes Mahmoud A. Ghannoum, Ph.D., E.M.B.A., professor and director of the Center for Medical Mycology in the Department of Dermatology; Loretta B. Szczotka-Flynn, O.D., M.S., associate professor of ophthalmology and visual sciences; and Arne Rietsch, Ph.D., assistant professor of molecular biology and microbiology.

The Department of Ophthalmology and Visual Sciences is part of the Visual Sciences Research Center, which encompasses more than 40 vision researchers in 18 departments at Case Western Reserve University and University Hospitals Case Medical Center campus, including pharmacology, pathology, molecular biology, epidemiology and biostatistics, chemistry and biomedical engineering.


'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Director of UT Southwestern center honored with first international neurology medal
2. Dynatronics to Supply Western Rehabilitation Health Networks 114 Clinics
3. Northwestern Memorial HealthCare and Lake Forest Hospital Sign Affiliation Agreement
4. Motorolas 802.11n Wireless LAN Solution Improves Patient Care and Wireless Security at Memorial Medical Center of Western Michigan
5. Community Health Centers and Western Governors University Partner to Address RN Shortage
6. Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation
7. Join WQED Pittsburgh and The Press Club of Western Pennsylvania in Celebrating National Healthy Aging(R) Month and Kick Off Active Aging Week September 21-27
8. Catalyst Pharmaceutical Partners Licenses Exclusive Rights to New Class of GABA Aminotransferase Inhibitors From Northwestern University
9. UT Southwestern Responds to VA Announcement
10. Rabies Vaccination Program Underway in Western Pennsylvania
11. AHRF and Northwestern University to Present a Lecture on Hearing and Hearing Loss on August 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... Butler Mobility ... the Stannah Stairlift and other Butler products. Ken was impressed with the safety ... agreed to endorse the product on his show. This endorsement by Ken Matthews ...
(Date:2/18/2017)... ... February 18, 2017 , ... A ... information and contact points to easily connect elderly veterans of America's armed forces ... elder-care funding. It also conveys material on this year's increase in the Veterans ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network ... prescribing of controlled and non-controlled substances plus the ability to manage orders on ... United States now accept electronic prescriptions, according to the Office of the National ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... February 17, 2017 ... ... Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? ...
(Date:2/17/2017)... ... 2017 , ... MAP Revenue Cycle Solutions (MAP RCS), a ... promoted to Chief Executive Officer. , The need for maximizing reimbursements while ... demands the transition from pay-for-service to pay-for-performance models. By delivering efficient and effective ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Inc. (NYSE: DVA ) today announced results for ... Net income attributable to DaVita Inc. for the quarter ... $0.80 per share and $880 million, or $4.29 per share, ... Inc. for the quarter and year ended December 31, 2016, ... $0.98 per share, and $789 million, or $3.85 per share, ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
Breaking Medicine Technology: